Mergers and Acquisitions

Anti-monopoly guidelines are set forth regarding the active pharmaceutical ingredient sector

Kainan Zhang and Junting Lei of Haiwen & Partners highlight the main PRC foreign exchange regulatory requirements of different types of cross-border investment and trade by domestic and foreign individuals and institutions under capital and current accounts.

2021 regulatory trends in China, including antitrust, data privacy, sanctions, healthcare, PE/VC, capital markets, IP, banking & finance, TMT and arbitration.

China joins the WIPO treaty on protecting industrial designs; Hong Kong, mainland M&A hits record heights in 2021 despite regulatory headwinds; and e-CNY to be piloted in retail shops across Hong Kong

Fay Zhou and Arthur Peng of Linklaters review major developments in China's anti-trust regulations that aim to offer clearer guidance and more efficient enforcement actions that can impact on this area of law for the next decade. These developments include stronger deterrence, expanded substantive prohibitions, public interest litigation and a firmer stance against consolidation.

With the entrenchment of reciprocal US-China sanctions and export controls in the past year, counsel have helped clients enact fundamental changes to their approach to making deals, from contractual terms to due diligence

VIE overseas listings require government consent

Foreign investors are allowed to conduct social surveys

The U.S. adds 12 Chinese entities to its export blacklist; Rules regulating listed companies to be consolidated; Didi ordered by regulators to delist from NYSE